TRXB · TRex Bio, Inc. · Insider Trading
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-10-13 | SVLSF VI, LLC |
10% Owner |
Other↑
Filing footnotes — Common Stock (Indirect)
The shares are held directly by SV Life Sciences Fund VI, L.P. ("SV Fund VI"). SV Life Sciences Fund VI (GP), L.P. (the "GP LP") is the general partner of SV Fund VI, and SVLSF VI, LLC ("SVLSF") is the general partner of GP LP. Investment and voting decisions of SV Fund VI are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership except to the extent of its pecuniary interest, and this report is not an admission of beneficial ownership for any other purpose. |
Common Stock
(I)
|
475,411 |
| 2026-10-13 | SVLSF VI, LLC |
10% Owner |
Other↓
Filing footnotes — Series A Preferred Stock (Indirect)
On October 13, 2026, 3.8649 shares of preferred stock automatically converted into one share of common stock upon the closing of the issuer's initial public offering, for no additional consideration. The preferred stock has no expiration date. The shares are held directly by SV Life Sciences Fund VI, L.P. ("SV Fund VI"). SV Life Sciences Fund VI (GP), L.P. (the "GP LP") is the general partner of SV Fund VI, and SVLSF VI, LLC ("SVLSF") is the general partner of GP LP. Investment and voting decisions of SV Fund VI are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership except to the extent of its pecuniary interest, and this report is not an admission of beneficial ownership for any other purpose. |
Series A Preferred Stock
(I)
|
1,574,074 |
| 2026-10-13 | SVLSF VI, LLC |
10% Owner |
Other↑
Filing footnotes — Common Stock (Indirect)
The shares are held directly by SV Life Sciences Fund VI Strategic Partners, L.P. ("SV Strategic Partners VI"). GP LP is the general partner of SV Strategic Partners VI, and SVLSF is the general partner of GP LP. Investment and voting decisions of SV Strategic Partners VI are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership except to the extent of its pecuniary interest, and this report is not an admission of beneficial ownership for any other purpose. |
Common Stock
(I)
|
53,892 |
| 2026-10-13 | SVLSF VI, LLC |
10% Owner |
Other↓
Filing footnotes — Series B Preferred Stock (Indirect)
On October 13, 2026, 3.8649 shares of preferred stock automatically converted into one share of common stock upon the closing of the issuer's initial public offering, for no additional consideration. The preferred stock has no expiration date. The shares are held directly by SV Life Sciences Fund VI, L.P. ("SV Fund VI"). SV Life Sciences Fund VI (GP), L.P. (the "GP LP") is the general partner of SV Fund VI, and SVLSF VI, LLC ("SVLSF") is the general partner of GP LP. Investment and voting decisions of SV Fund VI are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership except to the extent of its pecuniary interest, and this report is not an admission of beneficial ownership for any other purpose. |
Series B Preferred Stock
(I)
|
475,411 |
| 2026-10-13 | SVLSF VI, LLC |
10% Owner |
Other↑
Filing footnotes — Common Stock (Indirect)
The shares are held directly by SV Life Sciences Fund VI Strategic Partners, L.P. ("SV Strategic Partners VI"). GP LP is the general partner of SV Strategic Partners VI, and SVLSF is the general partner of GP LP. Investment and voting decisions of SV Strategic Partners VI are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership except to the extent of its pecuniary interest, and this report is not an admission of beneficial ownership for any other purpose. |
Common Stock
(I)
|
16,277 |
| 2026-10-13 | Alexandria Venture Investments, LLC |
10% Owner |
Other↓
Filing footnotes — Series B Preferred Stock (Direct)
Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.8649 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 13, 2026, for no additional consideration. The shares had no expiration date. |
Series B Preferred Stock
|
3,480,387 |
| 2026-10-13 | Alexandria Venture Investments, LLC |
10% Owner |
Buy↑
|
Common Stock
|
178,571 |
| 2026-10-13 | SVLSF VI, LLC |
10% Owner |
Other↑
Filing footnotes — Common Stock (Indirect)
The shares are held directly by SV Life Sciences Fund VI, L.P. ("SV Fund VI"). SV Life Sciences Fund VI (GP), L.P. (the "GP LP") is the general partner of SV Fund VI, and SVLSF VI, LLC ("SVLSF") is the general partner of GP LP. Investment and voting decisions of SV Fund VI are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership except to the extent of its pecuniary interest, and this report is not an admission of beneficial ownership for any other purpose. |
Common Stock
(I)
|
1,574,074 |
| 2026-10-13 | MARCUS JOEL S |
Director, Executive Chairman |
Other↓
Filing footnotes — Series B Convertible Preferred Stock (Direct)
On October 13, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 3.8649-to-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. |
Series B Convertible Preferred Stock
|
161,828 |
| 2026-10-13 | SVLSF VI, LLC |
10% Owner |
Other↓
Filing footnotes — Series B Preferred Stock (Indirect)
On October 13, 2026, 3.8649 shares of preferred stock automatically converted into one share of common stock upon the closing of the issuer's initial public offering, for no additional consideration. The preferred stock has no expiration date. The shares are held directly by SV Life Sciences Fund VI Strategic Partners, L.P. ("SV Strategic Partners VI"). GP LP is the general partner of SV Strategic Partners VI, and SVLSF is the general partner of GP LP. Investment and voting decisions of SV Strategic Partners VI are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership except to the extent of its pecuniary interest, and this report is not an admission of beneficial ownership for any other purpose. |
Series B Preferred Stock
(I)
|
16,277 |
| 2026-10-13 | SVLSF VI, LLC |
10% Owner |
Other↓
Filing footnotes — Series A Preferred Stock (Indirect)
On October 13, 2026, 3.8649 shares of preferred stock automatically converted into one share of common stock upon the closing of the issuer's initial public offering, for no additional consideration. The preferred stock has no expiration date. The shares are held directly by SV Life Sciences Fund VI Strategic Partners, L.P. ("SV Strategic Partners VI"). GP LP is the general partner of SV Strategic Partners VI, and SVLSF is the general partner of GP LP. Investment and voting decisions of SV Strategic Partners VI are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership except to the extent of its pecuniary interest, and this report is not an admission of beneficial ownership for any other purpose. |
Series A Preferred Stock
(I)
|
53,892 |
| 2026-10-13 | SVLSF VI, LLC |
10% Owner |
Other↓
Filing footnotes — Series B Preferred Stock (Indirect)
On October 13, 2026, 3.8649 shares of preferred stock automatically converted into one share of common stock upon the closing of the issuer's initial public offering, for no additional consideration. The preferred stock has no expiration date. The shares are held directly by SV Trex Coinvestment, L.P. ("SV Coinvestment"). GP LP is the general partner of SV Coinvestment, and SVLSF is the general partner of GP LP. Investment and voting decisions of SV Coinvestment are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership and this report is not an admission of beneficial ownership for any other purpose. |
Series B Preferred Stock
(I)
|
669,939 |
| 2026-10-13 | Alexandria Venture Investments, LLC |
10% Owner |
Other↓
Filing footnotes — Series A-3 Preferred Stock (Direct)
Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.8649 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 13, 2026, for no additional consideration. The shares had no expiration date. |
Series A-3 Preferred Stock
|
1,033,541 |
| 2026-10-13 | SVLSF VI, LLC |
10% Owner |
Other↑
Filing footnotes — Common Stock (Indirect)
The shares are held directly by SV Trex Coinvestment, L.P. ("SV Coinvestment"). GP LP is the general partner of SV Coinvestment, and SVLSF is the general partner of GP LP. Investment and voting decisions of SV Coinvestment are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership and this report is not an admission of beneficial ownership for any other purpose. |
Common Stock
(I)
|
669,939 |
| 2026-10-13 | MARCUS JOEL S |
Director, Executive Chairman |
Other↑
Filing footnotes — Common Stock (Direct)
On October 13, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 3.8649-to-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. |
Common Stock
|
41,871 |
| 2026-10-13 | Alexandria Venture Investments, LLC |
10% Owner |
Other↑
Filing footnotes — Common Stock (Direct)
Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.8649 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 13, 2026, for no additional consideration. The shares had no expiration date. |
Common Stock
|
1,167,930 |
| 2026-10-08 | Gallagher Carol Giltner |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date. |
Stock Option (Right to Buy)
|
17,500 |
| 2026-10-08 | SVLSF VI, LLC |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
The shares are held directly by SV Life Sciences Fund VI, L.P. ("SV Fund VI"). SV Life Sciences Fund VI (GP), L.P. (the "GP LP") is the general partner of SV Fund VI, and SVLSF VI, LLC ("SVLSF") is the general partner of GP LP. Investment and voting decisions of SV Fund VI are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership except to the extent of its pecuniary interest, and this report is not an admission of beneficial ownership for any other purpose. Represents shares purchased by SV Fund VI in the issuer's initial public offering. |
Common Stock
(I)
|
89,783 |
| 2026-10-08 | Ross Michael Jay |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date. |
Stock Option (Right to Buy)
|
17,500 |
| 2026-10-08 | Coy Travis Alan |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date. |
Stock Option (Right to Buy)
|
17,500 |
| 2026-10-08 | Hirth Peter |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date. |
Stock Option (Right to Buy)
|
17,500 |
| 2026-10-08 | Gilmore Julie Ann |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date. |
Stock Option (Right to Buy)
|
17,500 |
| 2026-10-08 | MARCUS JOEL S |
Director, Executive Chairman |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date. |
Stock Option (Right to Buy)
|
17,500 |
| 2026-10-08 | SVLSF VI, LLC |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
The shares are held directly by SV Life Sciences Fund VI Strategic Partners, L.P. ("SV Strategic Partners VI"). GP LP is the general partner of SV Strategic Partners VI, and SVLSF is the general partner of GP LP. Investment and voting decisions of SV Strategic Partners VI are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership except to the extent of its pecuniary interest, and this report is not an admission of beneficial ownership for any other purpose. Represents shares purchased by SV Strategic Partners VI in the issuer's initial public offering. |
Common Stock
(I)
|
3,074 |